Unknown

Dataset Information

0

A trifluoromethyl analogue of celecoxib exerts beneficial effects in neuroinflammation.


ABSTRACT: Celecoxib is a selective cyclooxygenase-2 (COX2) inhibitor. We have previously shown that celecoxib inhibits experimental autoimmune encephalomyelitis (EAE) in COX-2-deficient mice, suggestive for a mode of action involving COX2-independent pathways. In the present study, we tested the effect of a trifluoromethyl analogue of celecoxib (TFM-C) with 205-fold lower COX-2 inhibitory activity in two models of neuroinflammation, i.e. cerebellar organotypic cultures challenged with LPS and the EAE mouse model for multiple sclerosis. TFM-C inhibited secretion of IL-1?, IL-12 and IL-17, enhanced that of TNF-? and RANTES, reduced neuronal axonal damage and protected from oxidative stress in the organotypic model. TFM-C blocked TNF-? release in microglial cells through a process involving intracellular retention, but induced TNF-? secretion in primary astrocyte cultures. Finally, we demonstrate that TFM-C and celecoxib ameliorated EAE with equal potency. This coincided with reduced secretion of IL-17 and IFN-? by MOG-reactive T-cells and of IL-23 and inflammatory cytokines by bone marrow-derived dendritic cells. Our study reveals that non-coxib analogues of celecoxib may have translational value in the treatment of neuro-inflammatory conditions.

SUBMITTER: Di Penta A 

PROVIDER: S-EPMC3859644 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature

altmetric image

Publications

A trifluoromethyl analogue of celecoxib exerts beneficial effects in neuroinflammation.

Di Penta Alessandra A   Chiba Asako A   Alloza Iraide I   Wyssenbach Ane A   Yamamura Takashi T   Villoslada Pablo P   Miyake Sachiko S   Vandenbroeck Koen K  

PloS one 20131211 12


Celecoxib is a selective cyclooxygenase-2 (COX2) inhibitor. We have previously shown that celecoxib inhibits experimental autoimmune encephalomyelitis (EAE) in COX-2-deficient mice, suggestive for a mode of action involving COX2-independent pathways. In the present study, we tested the effect of a trifluoromethyl analogue of celecoxib (TFM-C) with 205-fold lower COX-2 inhibitory activity in two models of neuroinflammation, i.e. cerebellar organotypic cultures challenged with LPS and the EAE mous  ...[more]

Similar Datasets

| S-EPMC5543406 | biostudies-literature
| S-EPMC6778705 | biostudies-literature
| S-EPMC6996349 | biostudies-literature
| S-EPMC2189720 | biostudies-other
| S-EPMC4010081 | biostudies-literature
| S-EPMC7809053 | biostudies-literature
| S-EPMC5908847 | biostudies-other
| S-EPMC3277311 | biostudies-literature
| S-EPMC3654564 | biostudies-literature
| S-EPMC7519200 | biostudies-literature